> Skip repeated content
photo of Ugur M. Ayturk, PhD

Ugur M. Ayturk, PhD

About Dr. Ayturk

Dr. Ugur Ayturk joined Hospital for Special Surgery in Fall 2017 as an Assistant Scientist. Prior to coming to HSS, Dr. Ayturk was an Instructor in Orthopaedic Surgery at Boston Children's Hospital and Harvard Medical School. He completed his PhD work at Colorado State University, and trained as a postdoctoral fellow in the Department of Orthopaedic Surgery at Boston Children's Hospital.


Our goal is to develop an improved understanding of osteoblasts, and use this knowledge to enhance their bone forming capabilities. We are specifically interested in how osteoblasts differentiate from mesenchymal precursors, and how their activities and molecular identity are altered under genetic and environmental perturbations. We use a multitude of approaches including transcriptional profiling (bulk and single cell RNA-seq), genetic modification of mouse models and primary cell culture in our investigations.


Musculoskeletal Integrity Program

Department of Orthopaedic Surgery, Weill Cornell Medicine



Assistant Scientist, Musculoskeletal Integrity Program
Assistant Professor of Physiology and Biophysics in Orthopaedic Surgery, Weill Cornell Medicine


Department of Orthopaedic Surgery, Weill Cornell Medicine


Phd, Colorado State University



Publications by Dr. Ayturk

Selected Journal Articles

Huang R, Balu AR, Molitoris KH, White JP, Robling AG, Ayturk UM*, Baht GS*. The role of Meteorin-like in skeletal development and bone fracture healing. J Orthop Res, in press, 2022. (* Corresponding authors)

Xia Y, Sokhi UK, Bell RD, Pannellini T, Turajane K, Niu Y, Frye L, Chao M, Ayturk U, Otero M, Bostrom M, Oliver D, Yang X, Ivashkiv LB. Immune and repair responses in joint tissues and lymph nodes after knee arthroplasty surgery in mice. Journal of Bone and Mineral Research, 36: 1765-1780, 2021.

Vesprey A, Suh ES, Göz Aytürk D, Yang X, Rogers M, Sosa B, Niu Y, Kalajzic I, Ivashkiv LB, Bostrom MPG, Ayturk UM*. Tmem100- and Acta2-lineage cells contribute to implant osseointegration in a mouse model. Journal of Bone and Mineral Research, 36: 1000-1011, 2021 (* Corresponding author).

Diegel CR, Hann S, Ayturk UM, Hu JCW, Lim KE, Droscha CJ, Madaj ZB, Foxa GE, Izaguirre I, Transgenics Core VVA, Paracha N, Pidhaynyy B, Dowd TL, Robling AG, Warman ML, Williams BO. An osteocalcin-deficient mouse strain without endocrine abnormalities. PLoS Genetics, 16: e1008361, 2020.

Ayturk UM*, Scollan JP, Ayturk DG, Suh ES, Vesprey A, Jacobsen CM, Pajevic PD, Warman ML. Single cell RNA sequencing of calvarial and long bone endorcortical cells. Journal of Bone and Mineral Research, 35: 1981-1991, 2020 (* Corresponding author).

Ayturk UM, Sieker JT, Haslauer CM, Proffen BL, Weissenberger MH, Warman ML, Fleming BC, Murray MM. Proteolysis and cartilage development are activated in the synovium after surgical induction of post traumatic osteoarthritis. PLoS One, 15: e0229449, 2020.

Ayturk UM*, Couto JA*, Hann S, Mulliken JB, Williams KL, Huang Y, Fishman SJ, Boyd TK, Kozakewich HPW, Bischoff J, Greene AK, Warman ML. Somatic activating mutations in GNAQ and GNA11 are associated with congenital hemangioma. American Journal of Human Genetics 2016, 98: 789-795 (*Equal contribution by the authors).

Bowen ME, Ayturk UM, Kurek KC, Yang W, Warman ML. SHP2 regulates chondrocyte terminal differentiation, growth plate architecture, and skeletal cell fates. PLOS Genetics 2014, 10(5):e1004364.

Kedlaya R, Veera S, Horan DJ, Moss RE, Ayturk UM, Jacobsen CM, Bowen ME, Pazsty C, Warman ML and Robling AG. Sclerostin inhibition reverses skeletal fragility in an Lrp5 deficient mouse model of OPPG syndrome. Science Translational Medicine 2013, 5:211ra518.

Ayturk UM, Jacobsen CM, Christodoulou DC, Gorham J, Seidman JG, Seidman CE, Robling AG and Warman ML. An RNA-seq Protocol to Identify mRNA Expression Changes in Mouse Diaphyseal Bone: Applications in Mice with Bone Property Altering Lrp5 Mutations. Journal of Bone and Mineral Research 2013, 28: 2081-93.

For more publications, please see the PubMed listing.

Industry Relationships

Industry Relationships

HSS has a long history of supporting appropriate relationships with industry because they advance HSS's mission to provide the highest quality patient care, improve patient mobility, and enhance the quality of life for all, and to advance the science of orthopedic surgery, rheumatology, and their related disciplines through research and education.

As of May 11, 2024, Dr. Ayturk reported no relationships with the healthcare industry.

HSS and its physicians make this information available to patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest and Commitment Policy prohibits physicians from collecting royalties on products they develop that are used on patients at HSS.